oral bpc-157 bioavailability study of bpc 157 Pharmacokinetics, distribution, metabolism, and excretion body-protective compound 157, a potential drug for treating various wounds, in rats and dogs Injection vs Oral Peptide: – will bpc 157 show up

Poor interobserver agreement between pathologists on the grade of dysplasia (particularly LGD) Variable natural predictive value of dysplasia, with variable progression rates reported for different cohorts for the same grade of dysplasia Patchy and subtle distribution of advanced dysplasia, so that sampling error is likely during surveillance Despite these limitations, the grade of dysplasia (no dysplasia, LGD, or HGD) is the primary clinical risk-stratification tool (Figure 2.5)

rather, this is a clinicopathologic condition that also requires symptoms of esophageal dysfunction for the diagnosis

Kanehisa M, Goto S

Yes it has been on the WADA Prohibited List since January 2022

A 2020 systematic review in Peptides identified only three Phase I human trials for BPC-157, none of which focused on anorectal conditions